Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation

Drug Delivery

Volumn 19, Issue 1, 2012, Pages 11-20

  Utreja, Puneet ^a   Jain, Subheet ^a   Tiwary, A K ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

cytotoxicity; elastic liposomes; intracellular uptake; Paclitaxel; single and repeated dose toxicity studies

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE ORANGE; CREMOPHOR; LIPOSOME; PACLITAXEL;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSAFETY; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; ELASTICITY; FEMALE; GLYCEROL; HUMANS; INTRACELLULAR FLUID; LIPOSOMES; MALE; MICE; PACLITAXEL; PHARMACEUTICAL VEHICLES; RANDOM ALLOCATION; TOXICITY TESTS, ACUTE;

EID: 84855416403     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.621990     Document Type: Article

References (30)

1. Armstrong, D., Bundy, B., Wenzel, L. (2006). Phase iii randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage iii ovarian cancer: A gynecologic oncology group study. N Engl J Med. 354:34-43.
2. Cevc, G., Blume, G., Schatzlein, A. (1997). Transfersomes mediated Tran epidermal delivery improves the regiospecifcity and biological activity of corticosteroids in vivo. J Contr Rel. 45:211-26.
3. Ermolaeva, L.A., Dubskaya, T.Y., Fomina, T.I., Vetoshkina, T.V., Goldberg, V.E. (2008). Toxic efect of an antitumor drug paclitaxel on morphofunctional characteristics of the liver in rats. Bull Exp Biol Med. 145:225-8.
4. Fang, J.Y., Lin, H.H., Hsu, L.R., Tsai, Y.H. (1997). Characterization and stability of various liposome-encapsulated enoxacin formulations. Chem Pharm Bull. 45:1504-9.
5. Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 37:1590-8. (Pubitemid 32778603)
6. Hamilton, M.A., Russo, R.C., Turston, R.C. (1977). Trimmed Spearman-karber method for estimating median lethal concentration in toxicity bioassays. Env Sci Technol. 7:714-9. (Pubitemid 8167560)
7. Jain, S., Jain, N.K., Tiwary, A.K. (2008). PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr Drug Del. 5:275-81.
8. Jain, S., Jain, P., Umamaheshwari, R.B., Jain, N.K. (2003). Transfersomes-A novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm. 29:1013-26. (Pubitemid 37346103)
9. Kim, S.C., Kim, D.W., Shim, Y.H., Bang, J.S, Oh, H.S., Wan, K.S. (2001). In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efcacy. J Contr Rel. 72:191-202. (Pubitemid 32522357)
10. Lu, J., Liong, M., Sherman, S., Xia, T., Kovochich, M., Nel, A.E., Zink, J.I., Tamanoi, F. (2007). Mesoporous silica nanoparticles for cancer therapy: Energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnol. 3:89-95
11. Mackay, H.J., Provencheur, D., Heywood, M., Tu, D., Eisenhauer, E.A., Oza, A.M., Meyer, R. (2011). Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer. Curr Oncol. 18:84-90.
12. Miglietta, A., Roberta, C., Claudia, B., Gabriel, L., Gasco, M.R. (2002). Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm. 210:61-7. (Pubitemid 32332642)
13. Park, J.H., Chi, S.C., Lee, W.S., Lee, W.M., Koo, Y.B., Yong, C.S., Choi, H.G., Woo, J.S. (2009). Toxicity studies of Cremophor-free paclitaxel solid dispersion formulated by a supercritical anti solvent process. Arch Pharm Res. 32:139-48.
14. Perdue, J.D., Seaton, P.J., Tyrell, J.A., DeVido, D.R. (2006). The removal of Cremphor EL from paclitaxel for quantitative analysis by HPLC-UV. J Pharm Biomed Anal. 41:117-23.
15. Rodrigues, D.G., Maria, D.A., Fernandes, D.C., Valduga, C.J., Couto, R.D., Ibanez, O.C. (2005). Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 55:565-76. (Pubitemid 40674632)
16. Scong, H., Jang, M., Wientjus, G., Jessie, L. (2001). Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 19:113-23.
17. Sharma, A., Mayhew, E., Straubinger, R.M. (1993). Anti-tumor efect of taxol-containg liposomes in a taxol-resistant murine tumor model. Cancer Res. 53:5877-81. (Pubitemid 24006153)
18. Shimomura, T., Fujiwara, H., Ikawa, S., Kigawa, J., Terakawa, N. (1998). Efect of Taxol on blood cells. Lancet. 352:541-2.
19. Singla, A.K., Garg, A., Aggerwal, D. (2002). Paclitaxel and its formulations. Int J Pharm. 235:179-92. (Pubitemid 34185449)
20. Spratlin, J., Sawyer, M.B. (2007). Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hemat. 61:222-9. (Pubitemid 46329429)
21. Tannock, I.F. (2001). Tumor physiology and drug resistance. Cancer Metastasis Rev. 20:123-32. (Pubitemid 34074688)
22. Taxol (Paclitaxel) Injection, Oncology Products Information, Bristol-Myers Squibb (Oncology) (2000). Princeton, NJ.
23. Todd, J.A., Modest, E.J., Rossow, P.W., Tokes, J.A. (1982). Liposome encapsulation enhancement of methotrexate sensitivity in a transport resistant human leukemic cell line. Biochem Pharmacol. 34:541-6. (Pubitemid 12125473)
24. NCI, USA guidelines. (2006). NCI clinical announcement: Intra peritoneal chemotherapy for ovarian cancer. Bethesda, MD: National Cancer Institute. Available online at: ctep.cancer.gov/highlights/docs/clin-annc-010506.pdf; accessed 17 December 2010.
25. Utreja, P. , Jain, S., Tiwary, A.K. (2011). Localized delivery of paclitaxel using elastic liposomes: Formulation development and evaluation. Drug Deliv. 18:367-76
26. Washington, C. (1989). Evaluation of the non-sink dialysis method for the measurement of drug release from colloids efect of drug partition. Int J Pharm. 56:71-4. (Pubitemid 19274692)
27. Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.L., Trump, D., Baker, R., VanEcho, D.A., VonHof, D.D., Leyland-Jones, B. (1990). Hypersenstivity reactions from taxol. J Clin Oncol. 8:1263-8.
28. Yann, H., Miao, J., Du, Y.Z., You, J., Hu, F.Q., Zeng, S. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 348:137-45. (Pubitemid 350266242)
29. Zhang, J.Q., Zhang, J.R., Yang, H., Tan, Q.Y., Qin, S.R., Qiu, X.L. (2005). Lyophilized paclitaxel magneto liposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res. 22:573-83. (Pubitemid 40603255)
30. Zhang, Z., Feng, S.S. (2006). The drug encapsulation efciency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials. 27:4025-33.